MR
MRK.US Merck & Company Inc
- Market cap
- USD 364B
- P/E
- 147.8x
- P/B
- 8.11x
- ROE
- -1.5%
- Dividend yield
- 2.24%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is MRK.US undervalued?
Graham numberThe Graham number of Merck & Company Inc cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Merck & Company Inc fundamental analysis
No fundamental analysis for Merck & Company Inc yet.
Merck & Company Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccine…
Full company profileMerck & Company Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Merck & Company Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 39.8B | 40.1B | 42.3B | 39.1B | 41.5B | 48.7B | 59.3B | 60.1B | 64.2B | 64.9B | 68.0B |
| Gross Profit | 25.8B | 27.2B | 28.8B | 27.1B | 27.9B | 35.1B | 41.9B | 44.0B | 49.0B | 46.7B | 51.7B |
| Operating Income | 5.50B | 6.80B | 8.93B | 7.93B | 5.55B | 13.2B | 18.3B | 2.95B | 20.2B | 23.5B | 4.03B |
| EBITDA | 10.8B | 12.0B | 14.0B | 16.0B | 10.2B | 17.9B | 21.3B | 6.91B | 25.7B | 28.3B | 7.34B |
| Net Income | 3.92B | 2.39B | 6.22B | 9.84B | 7.07B | 13.0B | 14.5B | 365M | 17.1B | 18.3B | -680M |
| EPS | 1.41 | 0.87 | 2.32 | 3.82 | 2.78 | 5.14 | 5.71 | 0.14 | 6.74 | 7.28 | -0.27 |
| Balance Sheet | |||||||||||
| Total Assets | 95.4B | 87.9B | 82.6B | 84.4B | 91.6B | 106B | 109B | 107B | 117B | 137B | 133B |
| Total Liabilities | 55.1B | 53.3B | 55.8B | 58.4B | 66.2B | 67.4B | 63.1B | 69.0B | 70.7B | 84.2B | 87.8B |
| Shareholders' Equity | 40.1B | 34.3B | 26.7B | 25.9B | 25.3B | 38.2B | 46.0B | 37.6B | 46.3B | 52.6B | 44.9B |
| Cash & Short-term Investments | 14.3B | 8.50B | 8.86B | 10.5B | 8.05B | 8.10B | 13.2B | 7.09B | 13.7B | 14.6B | 9.65B |
| Total Debt | 24.8B | 24.4B | 25.1B | 27.4B | 33.4B | 34.6B | 32.0B | 36.3B | 38.3B | 50.5B | 53.8B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 10.4B | 6.45B | 10.9B | 13.4B | 10.3B | 14.1B | 19.1B | 13.0B | 21.5B | 16.5B | 21.1B |
| Capital Expenditure | 1.61B | 1.89B | 2.62B | 3.47B | 4.68B | 4.45B | 4.39B | 3.86B | 3.37B | 4.11B | 3.90B |
| Free Cash Flow | 8.76B | 4.56B | 8.31B | 9.97B | 5.57B | 9.66B | 14.7B | 9.14B | 18.1B | 12.4B | 17.2B |
| Ratios | |||||||||||
| ROE | 9.8% | 7.0% | 23.3% | 38.0% | 27.9% | 34.2% | 31.6% | 1.0% | 37.0% | 34.7% | -1.5% |
| ROA | 4.1% | 2.7% | 7.5% | 11.7% | 7.7% | 12.3% | 13.3% | 0.3% | 14.6% | 13.3% | -0.5% |
| Net Profit Margin | 9.8% | 6.0% | 14.7% | 25.2% | 17.0% | 26.8% | 24.5% | 0.6% | 26.7% | 28.1% | -1.0% |
| Debt to Equity | 0.62x | 0.71x | 0.94x | 1.06x | 1.32x | 0.91x | 0.70x | 0.97x | 0.83x | 0.96x | 1.20x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Merck & Company Inc dividends
- Dividend yield
- 2.24%
- Forward dividend
- 3.40 USD
- Payout ratio
- 44.8%
- Ex-dividend date
- Sep 15, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | USD 8.18B | 3.26 | 44.8% |
| 2024 | USD 7.84B | 3.09 | 45.8% |
| 2023 | USD 7.45B | 2.92 | 2,039.7% |
| 2022 | USD 7.01B | 2.76 | 48.3% |
| 2021 | USD 6.61B | 2.60 | 50.7% |
| 2020 | USD 6.22B | 2.45 | 87.9% |
| 2019 | USD 5.70B | 2.21 | 57.9% |
| 2018 | USD 5.17B | 1.93 | 83.2% |
| 2017 | USD 5.17B | 1.88 | 215.8% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1048:1000 on Jun 3, 2021.
Who owns Merck & Company Inc
- Insiders 0.22%
- Institutions 82.58%
- Public & others 17.20%
- Shares outstanding 2.47B
- Free float 2.46B
Top funds holding MRK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 78.3M | 3.18% | -0.23% | Sep 2026 |
| Vanguard 500 Index Investor | 64.8M | 2.63% | -1.24% | Sep 2026 |
| iShares Core S&P 500 ETF | 32.9M | 1.33% | +0.17% | Oct 2026 |
| Fidelity 500 Index | 32.1M | 1.30% | +0.01% | Sep 2026 |
| Schwab US Dividend Equity ETF | 31.0M | 1.26% | +0.09% | Oct 2026 |
| State Street® SPDR® S&P 500® ETF | 30.1M | 1.22% | -0.25% | Oct 2026 |
| Vanguard MStar Value Index Investor | 23.5M | 0.95% | -0.45% | Sep 2026 |
| State Street®HlthCrSelSectSPDR®ETF | 18.1M | 0.73% | +0.88% | Oct 2026 |
| Vanguard Health Care Inv | 14.4M | 0.58% | -21.47% | Sep 2026 |
| Vanguard Dividend Appreciation ETF | 14.0M | 0.57% | -0.16% | Sep 2026 |
| Vanguard Institutional Index I | 13.1M | 0.53% | -1.16% | Sep 2026 |
| Vanguard Equity-Income Inv | 10.4M | 0.42% | -15.62% | Sep 2026 |
| Vanguard High Dividend Yield ETF | 10.1M | 0.41% | +0.28% | Sep 2026 |
| American Funds Washington Mutual A | 8.94M | 0.36% | +8.53% | Sep 2026 |
| Vanguard Health Care ETF | 7.55M | 0.31% | +0.13% | Sep 2026 |
| Vanguard Dividend Growth Inv | 6.96M | 0.28% | -4.89% | Sep 2026 |
| State Street® SPDR® Port S&P 500® ETF | 6.86M | 0.28% | -0.07% | Oct 2026 |
| Strategic Advisers Fidelity US TtlStk | 6.63M | 0.27% | -5.84% | Sep 2026 |
| JPMorgan Large Cap Growth I | 6.60M | 0.27% | -0.91% | Sep 2026 |
| iShares Core S&P 500 ETF USD Acc | 5.92M | 0.24% | 0.00% | Oct 2026 |
Top institutions holding MRK.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 227M | 9.21% | +0.52% | Jun 2026 |
| Vanguard Capital Management, LLC | 161M | 6.54% | +0.21% | Jun 2026 |
| State Street Corp | 120M | 4.88% | +0.91% | Jun 2026 |
| Wellington Management Company LLP | 86.2M | 3.50% | +2.29% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 67.7M | 2.75% | +0.65% | Jun 2026 |
| Geode Capital Management, LLC | 60.7M | 2.46% | +1.99% | Jun 2026 |
| Charles Schwab Investment Management Inc | 54.4M | 2.21% | +9.24% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 48.6M | 1.97% | +2.12% | Jun 2026 |
| FMR Inc | 45.4M | 1.84% | +2.08% | Jun 2026 |
| JPMorgan Chase & Co | 43.9M | 1.78% | -17.15% | Jun 2026 |
| Fisher Asset Management, LLC | 38.5M | 1.56% | +45.69% | Jun 2026 |
| NORGES BANK | 37.0M | 1.50% | -2.63% | Jun 2026 |
| Bank of America Corp | 30.5M | 1.24% | -0.78% | Jun 2026 |
| Northern Trust Corp | 26.3M | 1.07% | -3.01% | Jun 2026 |
| The Goldman Sachs Group Inc | 22.1M | 0.90% | +9.64% | Jun 2026 |
| Franklin Templeton Inc | 19.5M | 0.79% | +20.17% | Jun 2026 |
| UBS Asset Mgmt Americas Inc | 19.5M | 0.79% | -4.25% | Jun 2026 |
| Legal & General Group PLC | 18.9M | 0.77% | -3.40% | Jun 2026 |
| Amvescap Plc. | 18.6M | 0.75% | -14.84% | Jun 2026 |
| T. Rowe Price Associates, Inc. | 18.5M | 0.75% | -19.63% | Jun 2026 |
Merck & Company Inc company profile
- Company name
- Merck & Company Inc
- Ticker
- MRK.US
- Exchange
- USA Stocks
- Listed since
- Jan 13, 1978
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 73,000
- Fiscal year end
- December
- Address
- 126 East Lincoln Avenue, Rahway, NJ, United States, 07065
- Phone
- 908 740 4000
- Website
- merck.com
About Merck & Company Inc
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.
Merck & Company Inc management
10- Mr. Robert M. Davis J.D.Chairman, President & CEO · born 1967
- Ms. Caroline A. LitchfieldExecutive VP & CFO · born 1969
- Ms. Jennifer L. Zachary J.D.Executive VP & General Counsel · born 1978
- Dr. Dean Y. Li M.D., Ph.D.Executive VP & President of Merck Research Laboratories · born 1963
- Mr. Dalton E. Smart IIISenior VP of Finance, Principal Accounting Officer & Global Controller · born 1967
- Mr. Gaurav K. GuptaExecutive Vice President and Chief Information & Digital Officer
- Mr. Peter DannenbaumVice President of Investor Relations
- Mr. Chirfi GuindoExecutive Vice President of Strategic Access, Policy & Communications · born 1966
- Ms. Betty D. LarsonExecutive VP & Chief Human Resources Officer · born 1976
- Mr. Richard R. DeLuca Jr.Executive VP & President of Merck Animal Health · born 1963